Table 3 Cox proportional hazards regression analysis of mortality: univariable and multivariable models for the entire cohort

Sex

Male

1

1

Female

0.86 (0.56–1.33)

1.13 (0.69–1.85)

Age (years)

< 60

1

1

≥ 60

0.76 (0.50–1.16)

0.62 (0.38–1.01)

Weigh (kg)

< 55

1

1

≥ 55

1.01 (0.66–1.54)

0.74 (0.46–1.18)

Nationality

The Han

1

1

Minority nationality

1.26 (0.58–2.73)

0.97 (0.41–2.32)

Tumor location

Rectum

1

1

Colon

0.61 (0.34–1.10)

0.59 (0.31–1.11)

TNM stage

I

1

1

II

3.87 (0.51–29.46)

3.39 (0.43–26.76)

III

6.41 (0.89–46.48)

4.54 (0.60–34.55)

IV

42.55 (5.67–319.14)

30.63 (3.85–243.65)

Tumor classification

The elevated

1

1

The ulcerative

1.32 (0.81–2.15)

1.46 (0.85–2.52)

The infiltrative

1.82 (1.00–3.32)

0.40 (0.06–2.91)

Histological type

Adenocarcinoma (NOS)

1

1

Special types of cancer

1.69 (1.01–2.81)

4.28 (0.55–33.31)

Degree of differentiation

High

1

1

Medium

1.03 (0.62–1.71)

1.17 (0.66–2.08)

Low

1.58 (0.81–3.06)

0.94 (0.40–2.20)

Lymphovascular invasion

No

1

1

Yes

1.95 (1.10–3.46)

2.07 (1.09–3.92)

ASA

II

1

1

III

1.15 (0.67–1.98)

0.86 (0.47–1.59)

Inhalation anesthetics

Sevoflurane

1

1

Isoflurane

1.68 (1.07–2.65)

1.96 (1.19–3.21)

Anesthesia time (h)

< 4.5

1

1

≥ 4.5

0.99 (0.65–1.52)

1.02 (0.47–2.22)

Duration of surgery (h)

< 3.5

1

1

≥ 3.5

0.97 (0.64–1.49)

0.85 (0.38–1.88)

Postoperative analgesia

No

1

1

Yes

0.52 (0.19–1.41)

0.44 (0.14–1.34)

Postoperative hospitalization days

< 13

1

1

≥ 13

1.26 (0.82–1.93)

1.20 (0.73–1.97)

IPS score

< 1

1

1

≥ 1

1.26 (0.79–2.00)

1.19 (0.72–1.98)

KM grade

High–grade inflammation

1

1

Low–grade inflammation

2.05 (1.34–3.15)

2.03 (1.20–3.43)